What Are Wall Street Analysts' Target Price for Becton, Dickinson and Company Stock?

Core Viewpoint - Becton, Dickinson and Company (BDX) is a leading medical technology firm with a market cap of $54.2 billion, facing stock underperformance compared to broader market indices despite reporting strong revenue growth and positive earnings guidance for fiscal 2026 [1][2][4]. Company Overview - BDX develops, manufactures, and sells a wide range of medical devices, laboratory equipment, and diagnostic products, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1]. Stock Performance - Over the past 52 weeks, BDX stock has decreased by 16.9%, while the S&P 500 Index has gained 14.5%. Year-to-date, BDX shares have declined by 15.3%, compared to a 16.5% rise in the S&P 500 [2][3]. Financial Performance - For the fourth quarter, BDX reported revenue of $5.9 billion, an 8.3% year-over-year increase, driven by strong demand in its medical and interventional segments. Adjusted EPS was $3.96, up from $3.81 a year earlier, slightly exceeding expectations [4]. Future Guidance - BDX has guided for fiscal 2026 adjusted EPS between $14.75 and $15.05, with analysts expecting a 3% year-over-year growth to $14.83 [4][5]. Analyst Ratings - Among 16 analysts covering BDX, the consensus rating is a "Moderate Buy," with six "Strong Buy" ratings, one "Moderate Buy," and nine "Holds." The company has a promising earnings surprise history, having beaten consensus estimates in the last four quarters [5]. Price Target - Piper Sandler analyst Jason Bednar reiterated a "Hold" rating on BDX and maintained a price target of $200 on the stock [6].